DC8331 |
GSK2256098
Featured
|
GSK2256098 is small molecule FAK kinase inhibitor. |
|
DC8491 |
GSK2879552
Featured
|
GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. |
|
DC10647 |
EPZ015938(pemrametostat)
Featured
|
GSK3326595(EPZ015938) is the first-in-class protein arginine methyltransferase-5 (PRMT5) inhibitor. |
|
DC2070 |
GSK690693
Featured
|
GSK690693 is a pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 2 nM, 13 nM, and 9 nM, respectively. |
|
DC7812 |
GSK923295
Featured
|
GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183. |
|
DC10033 |
H3B-6527
Featured
|
H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. |
|
DC8768 |
HMN-214
Featured
|
HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM. |
|
DC11262 |
IACS-010759
Featured
|
IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain. |
|
DC10174 |
Iberdomide
Featured
|
Iberdomide (CC-220) is a cereblon modulator in clinical development for systemic lupus erythematosis. Iberdomide exhibits an IC50 of 60 nM in TR-FRET cereblon binding assay. |
|
DC11303 |
CT7001 hydrochloride
Featured
|
ICEC0942 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. |
|
DC3130 |
ICG-001
Featured
|
ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro |
|
DC8111 |
Idarubicin Hydrochloride
Featured
|
Idarubicin Hcl is an anthracycline antibiotic and a DNA topoisomerase II (topo II) inhibitor. |
|
DC10538 |
IDH-305
Featured
|
IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. |
|
DC10098 |
IDO-IN-1
Featured
|
IDO-IN-1 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50 of 59 nM, shows activity in Hela cell (IC50=12 nM). |
|
DC9014 |
Ifosfamide |
Ifosfamide is a nitrogen mustard alkylating agent used in the treatment of cancer. |
|
DC4181 |
Imatinib mesylate
Featured
|
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. |
|
DC10406 |
Imisopasem manganese |
Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD. |
|
DC10918 |
INCB053914 |
INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively. |
|
DC7167 |
Capmatinib(INCB28060)
Featured
|
INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase. |
|
DC7429 |
INCB 8761
Featured
|
INCB8761(PF-4136309) is a potent, Selective, and orally bioavailable CCR2 antagonist. |
|
DC7171 |
INK-128(Sapanisertib)
Featured
|
INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms. |
|
DC5072 |
Duvelisib (IPI-145, INK1197)
Featured
|
IPI-145 is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. |
|
DC9829 |
IPI-549
Featured
|
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. |
|
DC5107 |
SB-715992 (Ispinesib)
Featured
|
Ispinesib (SB 715992) is a potent mitotic kinesin KSP (Eg5) inhibitor with a Ki and an IC50 of 0.6 and 4.1 nM, respectively. |
|
DC12378 |
Itacitinib(INCB039110)
Featured
|
Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis. |
|
DCAPI1510 |
Ixabepilone
Featured
|
Ixabepilone (Azaepothilone B; BMS 247550) is an epothilone B analog and nontaxane microtubule-stabilizing compound with clinical activity in a range of solid tumors. |
|
DC7175 |
JNJ-26854165 (Serdemetan)
Featured
|
JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. |
|
DC7177 |
JNJ 38877605
Featured
|
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. |
|
DC9272 |
K 858
Featured
|
K 858 is an ATP-uncompetitive mitotic kinesin Eg5 inhibitor, which does not effect microtubule dynamics. |
|
DC8247 |
KNK437
Featured
|
KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40. |
|